• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    8/2/24 9:00:00 AM ET
    $CLDI
    $GP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Construction/Ag Equipment/Trucks
    Consumer Discretionary
    Get the next $CLDI alert in real time by email

    ORLANDO, FL / ACCESSWIRE / August 2, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (NASDAQ:GP) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • GreenPower Motor: https://www.redchip.com/assets/access/gp_access

    • Calidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_access

    In an exclusive interview, Fraser Atkinson, CEO of GreenPower, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. GreenPower is a leading manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector. The Company has established a solid track record of sales growth, including more than 700 EV Stars, low-floor transit buses and school buses delivered to date, and maintains a significant order book that which can be satisfied with existing production capacity at its California and West Virginia manufacturing facilities and through contract manufacturing. GreenPower's competitive positioning, solid sales trajectory, accomplished leadership and favorable market dynamics underscore its potential for sustained growth and value creation in the rapidly evolving EV industry.

    Allan Camaisa, CEO of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Calidi is at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemic and localized OVs, leveraging engineered viruses to target and destroy cancer cells while arming the immune system for a comprehensive attack on tumors. Calidi's cell-based technologies uniquely protect OVs from immune system elimination, ensuring higher efficacy and opening the tumor microenvironment to treatment. This approach has shown promising efficacy in initial studies, while their breakthrough IV-based technology and direct tumor administration methods differentiate them within the oncology field.

    About GreenPower Motor Company, Inc.

    GreenPower designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo vans and a cab and chassis. GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose-built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. GreenPower was founded in Vancouver, Canada with primary operational facilities in southern California. Listed on the Toronto exchange since November 2015, GreenPower completed its U.S. IPO and NASDAQ listing in August 2020. For further information go to www.greenpowermotor.com.

    About Calidi Biotherapeutics

    Calidi Biotherapeutics (NYSE:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-407-644-4256
    info@redchip.com

    SOURCE: RedChip



    View the original press release on accesswire.com

    Get the next $CLDI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLDI
    $GP

    CompanyDatePrice TargetRatingAnalyst
    Calidi Biotherapeutics Inc.
    $CLDI
    11/22/2023$11.00Buy
    H.C. Wainwright
    Calidi Biotherapeutics Inc.
    $CLDI
    10/9/2023$9.00Outperform
    Robert W. Baird
    GreenPower Motor Company Inc.
    $GP
    2/15/2022$13.00Neutral → Buy
    ROTH Capital
    GreenPower Motor Company Inc.
    $GP
    11/15/2021$32.00 → $13.00Buy → Neutral
    ROTH Capital
    More analyst ratings

    $CLDI
    $GP
    SEC Filings

    View All

    Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    7/16/26 5:30:30 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GreenPower Motor Company Inc.

    6-K - GREENPOWER MOTOR Co INC. (0001584547) (Filer)

    7/10/26 6:37:02 PM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    SEC Form D filed by GreenPower Motor Company Inc.

    D - GREENPOWER MOTOR Co INC. (0001584547) (Filer)

    7/10/26 5:23:12 PM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    $CLDI
    $GP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Jackson Andrew C. bought $5,000 worth of shares (2,500 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:36 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Poma Eric E bought $50,000 worth of shares (25,000 units at $2.00) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:39 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Leftwich Scott bought $250,000 worth of shares (125,000 units at $2.00), increasing direct ownership by 2,212% to 130,650 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    8/25/25 8:47:37 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    $GP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Sanders Corazon (Corsee) D.

    3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    6/29/26 5:12:57 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Camaisa Allan sold $1,237 worth of shares (850 units at $1.46) (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    12/16/25 7:37:06 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Executive Officer Poma Eric E

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    9/5/25 7:56:29 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    $GP
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

    SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company’s Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Ms. Gurrola for the purchase of 100,000 shares with an exercise price of $0.15, which was the closing price of the Company’s common stock on July 6, 2026, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stock Options vesting on the one

    7/8/26 4:05:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

    SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders has an exceptional track record in developing new technologies," said Calidi Chairman of the Board Jim Schoeneck. "We believe her deep expertise in the clinical development of novel therapeutics will be highly valuable as Calidi advances CLD-401 and its RedTail platform into

    6/23/26 8:00:00 AM ET
    $CLDI
    $LEGN
    $RARE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    $GP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

    Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient in Q1 2027  Company demonstrated the versatility of the RedTail platform with new CLD-501 data demonstrating the simultaneous in situ delivery of a TROP-2-targeted tumor-localized T-cell engager (TCE) alongside a T-cell amplifiers. The Company is also advancing its EpCam-targeted In Situ TCE program. In Situ TCEs represent an important advancement of the RedTail platform Strengthened Board of Directors with addition of Corsee Sanders, Ph.D., former executive of Genentech/Roche and CelgeneComp

    7/21/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

    SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the "Reverse Stock Split"). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 31, 2026 under the existing symbol of "CLDI." The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 507. The decision to implement this stock split reflects the Company’s ai

    7/20/26 4:30:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

    SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company’s Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Ms. Gurrola for the purchase of 100,000 shares with an exercise price of $0.15, which was the closing price of the Company’s common stock on July 6, 2026, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stock Options vesting on the one

    7/8/26 4:05:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    $GP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

    11/22/23 7:15:52 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

    Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

    10/9/23 7:23:07 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GreenPower Motor upgraded by ROTH Capital with a new price target

    ROTH Capital upgraded GreenPower Motor from Neutral to Buy and set a new price target of $13.00

    2/15/22 8:52:35 AM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    $CLDI
    $GP
    Financials

    Live finance-specific insights

    View All

    Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

    Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026Presented new data on RedTail at the AACR conference in San Diego, CA detailing the use of the RedTail platform to create in vivo T-cell engagers that simultaneously express both a T-cell engager and a T-cell activator at high levels exclusively in the tumor microenvironment; presented new data on CLD-501, a TROP-2 in vivo T-cell engagerDemonstrated $1 million reduction in general and administrative expenses from Q1-2025 to Q1-2026Speaker presentation at ASGCT conference in Boston, MA highl

    5/14/26 4:10:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GreenPower Announces Issuance of Convertible Debentures and Series B Convertible Preferred Shares

    Not for Distribution to United States News Wire Services or for Dissemination in the United States VANCOUVER, BC, Jan. 29, 2026 /CNW/ -- GreenPower Motor Company Inc. (NASDAQ:GP) ("GreenPower" or the "Company"), a leading manufacturer and distributor of all-electric, purpose-built, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, today announces that it has converted (the "Debenture Offering") US$7,000,000 of principal and accrued interest of outstanding loans with certain related parties of the Company into convertible debentures of the Company (each, a "Debenture").

    1/29/26 12:00:00 PM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

    Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcomaRaised $4.6 million gross proceeds through a warrant inducement offering with existing investors that further strengthens the company's balance sheet and extends its runway SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics

    8/8/25 4:15:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    $GP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    11/14/24 2:05:25 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

    SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    9/11/24 4:04:09 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by GreenPower Motor Company Inc. (Amendment)

    SC 13G/A - GREENPOWER MOTOR Co INC. (0001584547) (Subject)

    2/9/23 10:59:20 AM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary